# Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

> **NCT02608112** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 291 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT02608112
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-31
- **Primary completion:** 2018-07-26
- **Final completion:** 2018-07-26
- **Target enrollment:** 291 (ESTIMATED)
- **Last updated:** 2020-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02608112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02608112, "Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02608112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*